

Changing Minds, Changing Systems: Promoting Compassionate Care for Opioid Use Disorder and HIV

Reference List

Ashford, R. D., Brown, A. M., & Curtis, B. (2018). The Language of Substance Use and Recovery: Novel Use of the Go/No-Go Association Task to Measure Implicit Bias. *Health communication*, 1-7.

American Society of Addiction Medicine (ASAM). (2020). *The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update*. Washington, DC: Author. Accessed July 16, 2026, from: <https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline>.

American Society of Addiction Medicine. (2024). *Treatment of Opioid Use Disorder Course*. Accessed May 14, 2026, from: <https://elearning.asam.org/products/treatment-of-opioid-use-disorder-course>.

Azzoni, L., Metzger, D., & Montaner, L. J. (2020). Effect of opioid use on immune activation and HIV persistence on ART. *J Neuroimmune Pharmacol*, 15(4), 643–657.
<https://doi.org/10.1007/s11481-020-09959-y>

Bart, G. (2012). Maintenance medication for opiate addiction: The foundation of recovery. *Journal of Addictive Diseases*, 31(3), 207–225.
<https://doi.org/10.1080/10550887.2012.694598>

Braeburn Pharmaceuticals. (2026). [Webpage]. *Brixadi*®. Accessed May 1, 2026, from: <https://www.brixadi.com/>.

Bukten, A., Skurtveit, S., Gossop, M., Waal, H., Stangeland, P., Havnes, I., & Clausen, T. (2012). Engagement with opioid maintenance treatment and reductions in crime. A longitudinal national cohort study. *Addiction*, 107(2), 393–399.
<https://doi.org/10.1111/j.1360-0443.2011-03637.x>

Burns, M., Tang, L., Chang, C. H., Kim, J. Y., Ahrens, K., Allen, L., Cunningham, P., Gordon, A. J., Jarlenski, M. P., Lanier, P., Mauk, R., McDuffie, M. J., Mohamoud, S., Talbert, J., Zivin, K., & Donohue, J. (2022). Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: A retrospective cohort study. *Addiction*, 117(12), 3079–3088. doi: 10.1111/add.15959. Epub 2022 Jun 13. PMID: 35652681; PMCID: PMC10683938.

California Department of Public Health. (2025). [Webpage]. *Signs of a Drug-Related Overdose*. Accessed December 15, 2025, from: <https://www.cdph.ca.gov/Programs/CCDPHP/sapb/Pages/Signs-of-overdose.aspx>.

Cantor, J., Griffin, B. A., & Levitan, B. (2024). Availability of medications for opioid use disorder in community mental health facilities. *JAMA Network Open*, 7(6), e2417545. <https://doi.org/10.1001/jamanetworkopen.2024.17545>

Carnevale Associates LLC. (2025). Info Brief: Emerging Drug Trends – Nitazenes, Tianeptine, and Synthetic Benzodiazepines. Available at: <https://www.carnevaleassociates.com/our-work/emerging-drug-trends-nitazenes-tianeptine-and-synthetic-benzodiazepines.html>.

Cazalis, A., Lambert, L., & Auriacombe, M. (2023). Stigmatization of people with addiction by health professionals: Current knowledge. A scoping review. *Drug Alcohol Depend Rep*, 24; 9, 100196. doi: 10.1016/j.dadr.2023.100196. PMID: 38023342; PMCID: PMC10656222.

Centers for Disease Control and Prevention. (2025). [Webpage]. *Estimated HIV Incidence and Prevalence*. Accessed May 1, 2026, from: <https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html>.

Centers for Disease Control and Prevention. (2024). [Webpage]. *Fentanyl Facts*. Accessed July 15, 2026, from: <https://www.cdc.gov/stop-overdose/caring/fentanyl-facts.html>.

Chu, C. (2019). *Ending the HIV & HCV Epidemics: A Critical Role for Substance Use Providers*. Newark, NJ: AIDS Education and Training Center National Coordinating Resource Center. Retrieved from: <https://aidsetc.org/resource/ending-hiv-hcv-epidemics-critical-role-substance-use-providers>.

Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2017). Increased use of heroin as an initiating opioid of abuse. *Addict Behav*, 74, 63–66. <https://doi.org/10.1016/j.addbeh.2017.030>

Commonwealth of Massachusetts Bureau of Substance Abuse Services. (2015). [Stephanies-Story](#).

Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. *Harv Rev Psychiatry*, 23(2), 63–75. <https://doi.org/10.1097/HRP0000000000000075>

COPE, Australia. (2017). Accessed from: <https://www.northcarolinahealthnews.org/2017/07/12/naloxone-101-works-using/>.

Corrigan, P. W., Mittal, D., Reaves, C. M., Haynes, T. F., Han, X., Morris, S., & Sullivan, G. (2014). Mental health stigma and primary care decisions. *Psychiatry Research*, 218(0), 35–38.

Crowley, R. Kirschner, N., Dunn, A. S., & Borenstein, S. S. (2017). Health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs: An American College of Physicians Paper. *Annals of Internal Medicine*, 166(10).

Cunningham, C. (2018). Opioids and HIV infection: From pain management to addiction treatment. *Topics in Antiviral Medicine*, 25(4), 143–146.

D’Onofrio, G., Pantalon, M. V., Degutis, L. C., Fiellin, D. A., & O’Connor, P. G. (2005). Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. *Acad Emerg Med*, 12(3), 249–256. <https://doi.org/10.1197/j.aem.2004.10.021>

Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016). A systematic review on the use of psychosocial interventions in conjunction with medications for opioid addiction. *J Addict Med*, 10(2), 93–103. <https://doi.org/10.1097/ADM.0000000000000193>

Dupouy, J., Palmaro, A., Fatséas, M., Auriacombe, M., Micallef, J., Oustric, S., & Lapeyre-Mestre, M. (2017). Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: A 7-year cohort study. *Ann Fam Med*, 15(4), 355–358. doi: 10.1370/afm.2098. PMID: 28694272; PMCID: PMC5505455.

End Stigma End HIV Alliance of San Antonio County. (2026). [Webpage] *End Stigma End HIV*. Accessed February 19, 2026, from: <https://endstigmaendhiv.com/>.

Evans, E., Li, L., Min, J., Huang, D., Urada, D., Liu, L., Hser, Y.-I., & Nosyk, B. (2015). Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. *Addiction*, 110(6), 996-1005. doi: 10.1111/add.12863. Epub 2015 Mar 15. PMID: 25644938; PMCID: PMC4452110.

Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O’connor, P. G., & Schottenfeld, R. S. (2006). Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. *New England Journal of Medicine*, 355(4), 365-374.

Fiellin, D., Weiss, L., Botsko, M., Egan, J., Altice, F., Bazerman, L. B., ... the BHIVES Collaborative. (2011). Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. *Journal of Acquired Immune Deficiency Syndromes*, 56(Suppl 1), S33–38.

Friedman, J. R., Palamar, J. J., Ciccarone, D., Gaines, T. L., Borquez, A., Shover, C. L., & Strathdee, S. A. (2025). Characterizing declines in US overdose deaths compared to exponential predictions. *medRxiv*. <https://doi.org/10.1101/2025.10.24.25338732>

Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. *N Engl J Med*, 349(10, 949-958. <https://doi.org/10.1056/NEJMoa022164>

Gearing, F. R., & Schweitzer, M. D. (1974). An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. *Am J Epidemiol*, 100(2), 101–112. <https://doi.org/10.1093/oxfordjournals.aje.a112012>

Goodyear, K., Haass-Koffler, C. L., & Chavanne, D. (2018). Opioid use and stigma: The role of gender, language, and precipitating events. *Drug and Alcohol Dependence*, 185, 339–346.

Grassi, G. (2024). The opioid epidemic continues while effective medication is underutilized. Accessed May 14, 2026, from: <https://www.ajmc.com/view/the-opioid-epidemic-continues-while-effective-medication-is-underutilized>.

Grasso, J., Taylor, K. P., & Cisneros, N. (2026). *Brief: HIV Stigma is Pervasive and Increasing among US Adults*. Los Angeles, CA: UCLA School of Law, Williams Institute.

Hankir, A. K., Northall, A., & Zaman, R. (2014). Stigma and mental health challenges in medical students. *BMJ Case Rep*, 2014, bcr2014205226.

Hatzenbuehler, M. L., Bellatorre, A., Lee, Y., Finch, B. K., Muennig, P., & Fiscella, K. (2014). Structural stigma and all-cause mortality in sexual minority populations. *Soc Sci Med*, 103, 33–41.

Headley, J. (2013). [Video]. It's Not About The Nail. Accessed February 19, 2026, from: [It's-Not-About-The-Nail](#).

HIV.gov. (2026). [Webpage]. *Substance Use and HIV Risk*. Accessed May 14, 2026, from: <https://www.hiv.gov/hiv-basics/hiv-prevention/reducing-risk-from-alcohol-and-drug-use/substance-use-and-hiv-risk>.

HIV.gov. (2025). [Webpage]. *U.S. Statistics*. Accessed May 1, 2026, from: <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>.

Hoffman K., Peyton M. L., Sumner M. Safety of a rapidly dissolving buprenorphine/naloxone sublingual tablet (BNX-RDT) for treatment of opioid dependence: a multicenter, open-label extension study. *J Addict Med* 2017; 11: 217–23.

Hulsey, J., Zawislak, K., Sawyer-Morris, G., & Earnshaw, V. (2023). Stigmatizing imagery for substance use disorders: A qualitative exploration. *Health Justice*, 11, 28.

<https://doi.org/10.1186/s40352-023-00229-6>

Ilyas, A. M., Ramtin, S., Ilyas, E. N., Solarz, M. K., Miller, A., Rae, L., Wink, J., Haroz, R., Weinstein, L., & Criner-Woozley, K. T. (2025). Philadelphia Consensus on the Surgical Management of Xylazine-Associated Wounds in People Who Use Drugs. *SurgiColl*.

<https://doi.org/10.58616/001c.140602>

Isaksson, A., Corker, E., Cotney, J., Hamilton, S., Pinfold, V., Rose, D., Rüşch, N., Henderson, C., Thornicroft, G., & Evans-Lacko, S. (2018). Coping with stigma and discrimination: Evidence from mental health service users in England. *Epidemiology and psychiatric sciences*, 27(6), 577–588.

Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. *Addiction*, 113(7), 1188–1209. <https://doi.org/10.1111/add.14180>

Kakko, J., Dybrandt Svanborg, K., Kreek, M. J., & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomized, placebo-controlled trial. *Lancet*, 361(9358), 662–668. [https://doi.org/10.1016/S0140-6736\(03\)12600](https://doi.org/10.1016/S0140-6736(03)12600)

Kelly, J. F., Dow, S. J., & Westerhoff, C. (2010). Does our choice of substance-related terms influence perceptions of treatment need? An empirical investigation with two commonly used terms. *Journal of Drug Issues*, 40(4), 805–818.

<https://doi.org/10.1177/002204261004000403>

Kelly, J. F., & Westerhoff, C. M. (2010). Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms.

International Journal of Drug Policy, 21(3), 202–207.

<https://doi.org/10.1016/j.drugpo.2009.10.010>

Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance. *Dialogues in Clinical Neuroscience*, 9(2), 199–206.

<https://doi.org/10.31887/DCNS.2007.9.2/hkleber>

Kling, M. A., Carson, R. E., Borg, L., Zametkin, A., Matochik, J. A., Schluger, J., Herscovitch, P., Rice, K. C., Ho, A., Eckelman, W. C., & Kreek, M. J. (2000). Opioid receptor imaging with positron emission tomography and [(18F)cyclofoxy in long-term, methadone-treated former heroin addicts. *J Pharmacol Exp Ther*, 295(3), 1070-1076. PMID: 11082442.

Krisnapura, S. R., McNeer, E., Loch, S. F., Reese, T., Dudley, J., Phillippi, J. C., Wiese, A. D., Dupont, W. D., Leech, A. A., & Patrick, S. W. (2025). Buprenorphine treatment in pregnancy and maternal-infant outcomes. *JAMA Health Forum*, 6(4.11), e25184.

<https://doi.org/10.1001/jamahealthforum.2025.1814>

Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2010). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled multicentre randomized trial. *Lancet*, 377(9776), 1506-1513.

Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Ann Intern Med*, 169(3), 137–145. <https://doi.org/10.7326/M17-3107>.

Li, W., Li, Q., Zhu, J., et al. (2013). White matter impairment in chronic heroin dependence: a quantitative DTI study. *Brain Res*, 1531, 58-64.

<https://doi.org/10.1016/j.brainres.2013.07.036>

Liu, J., Qin, W., Yuan, K., et al. (2011). Interaction between dysfunctional connectivity at rest and heroin cues-induced brain responses in male abstinent heroin-dependent individuals. *PloS One*, 6(10), e23098. <https://doi.org/10.1371/journal.pone.0023098>

Luoma J et al. (2007). An investigation of stigma in individuals receiving treatment for substance abuse. *Addictive Behaviors*.

MacArthur, G. J., S. Minozzi, N. Martin, P. Vickerman, S. Deren, J. Bruneau, L. Degenhardt, and M. Hickman. 2012. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. *BMJ* 345:e5945. [PMC Free Article]

Mattick, R. P., Breen, C., Kimber, J., & Davoli, M., (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev*, 2014(2), CD002207. <https://doi.org/10.1002/14651858.CD002207.pub4>

Mattick, R., Breen, C., Kimber, J., & Davoli, M. (2009). *Cochrane Database Systematic Reviews*, 3, rCD002209.

Moran, G., Knudsen, H., & Snyder, C. (2019). *Psychosocial supports in medication-assisted treatment: Site visit findings and conclusions, Appendix B*. Rockville, MD: U.S. Department of Health & Human Services, Office of the Assistant Secretary for Planning and Evaluation. Accessed July 16, 2026, from: <https://aspe.hhs.gov/basic-report/psychosocial-supports-medication-assisted-treatment-recent-evidence-and-current-practice>.

National Academies of Sciences, Engineering, and Medicine. (2019). *Medications for Opioid Use Disorder Save Lives*. Washington, DC: The National Academies Press.
<https://doi.org/10.17226/25310>

National Institute for Health Care Management (NIHCM) Foundation. (2023). Mini-Infographics: Xylazine in Fentanyl Deaths. Washington, DC: Author. Accessed July 15, 2026, from : <https://nihcm.org/publications/xylazine-in-fentanyl-deaths>.

National Institute on Drug Abuse. (2011). Heroin Research Report: Overview. Accessed July 8, 2026, from <https://nida.nih.gov/publications/research-reports/heroin/overview>.

National Institute on Drug Abuse. (2021). [Webpage]. *NIDAMED: Words Matter – Terms to Use and Avoid When Talking About Addiction*. Accessed July 15, 2026, from:
<https://nida.nih.gov/nidamed-medical-health-professionals/health-professionals-education/words-matter-terms-to-use-avoid-when-talking-about-addiction>.

National Institute on Drug Abuse. (2024). [Webpage]. *Opioids*. Accessed December 15, 2025, from: <https://nida.nih.gov/research-topics/opioids>.

Oxford Learner's Dictionaries. (2026). [Webpage]. *Stigma*. Accessed May 1, 2026, from:
<https://www.oxfordlearnersdictionaries.com/us/definition/english/stigma>.

Papudesi, B. N., Malayala, S. V., & Regina, A. C. (2023). Xylazine Toxicity. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK594271/>.

Peles, E., Schreiber, S. Rados, V., & Adelson, M. (2011). Low risk for hepatitis c seroconversion in methadone maintenance treatment. *Journal of Addiction Medicine* 5(3), 214–220. <https://doi.org/10.1097/ADM.0b013e31820e13dd>

Pierce, M., Bird, S. M., Hickman, M., Marsden, J., Dunn, G., Jones, A., & Millar, T. (2016). Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England. *Addiction*, 111(2), 298–308. <https://doi.org/10.1111/add.13193>

Poliwoda, S., Noor, N., Jenkins, J. S., Start, C., Steib, M., Hasoon, J., Varrassi, G., Urits, I., Kaye, A. M., and Kaye, A. D. (2022). Buprenorphine and its formulations: A comprehensive review. *Health Psychol Res*, 10(3), 37517.

Ponizovsky, A. M., & Grinshpoon, A. (2007). Quality of life among heroin users on buprenorphine versus methadone maintenance. *Am J Drug Alcohol Abuse*, 33(5), 31–42.
<https://doi.org/10.1080/00952990701523698>

Qiu, Y., Jiang, G., Su, H., et al. (2013). Progressive white matter microstructure damage in male chronic heroin dependent individuals: a DTI and TBSS study. *PloS One*, 8(5), e63212. <https://doi.org/10.1371/journal.pone.0063212>

Reed, M. K., Imperato, N. S., Bowles, J. M., Salcedo, V. J. Guth, A., & Rising, K. L. (2022). Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. *Drug Alcohol Depend Rep*, 4, 100074. <https://doi.org/10.1016/dadr.2022.100074>

Reyes, J. C., Negrón, J. L., Colón, H. M., Padilla, A. M., & Millán, M. Y. (2012). The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. *Journal of Urban Health*, 89(3), 519–526. <https://doi.org/10.1007/s11524-011-9662-6>

Rodríguez, N., Vargas Vidot, J., Panelli, J., Colón, H., Ritchie, B., & Yamamura, Y. (2008). GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. *Drug and Alcohol Dependence*, 96(3), 290–293. <https://doi.org/10.1016/j.drugalcdep.2008.03.005>

Salsitz, E., & Wiegand, T. (2016). Pharmacotherapy of opioid addiction: “Putting a real face on a false demon.” *Journal of Medical Toxicology*, 12, 58–63.

Schuckit, M. A. (2016). Treatment of opioid use disorders. *N Engl J Med*, 375(4), 357–368. <https://doi.org/10.1056/NEJMr1604339>

Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013). Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. *American Journal of Public Health*, 103(5), 917–922. <https://doi.org/10.2105/AJPH.2012.301049>

Schwartz, R. P., Jaffe, J. H., O’Grady, K. E., Kinlock, T. W., Gordon, M. S., Kelly, S. M., Wilson, M. E., & Ahmed, A. (2009). Interim methadone treatment: Impact on arrests. *Drug Alcohol Depend*, 103, 148–154. <https://doi.org/10.1016/j.drugalcdep.2009.03.007>

Schwartz, R. P., Kelly, S. M., O’Grady, K. E., Gandhi, D., & Jaffe, J. H. (2011). Interim methadone treatment compared to standard methadone treatment: 4-month findings. *Journal of Substance Abuse and Treatment*, 41(1), 21–29. <https://doi.org/10.1016/j.jsat.2011.01.008>

Shah M, & Huecker, M. R. (2023). Opioid Withdrawal. [Updated 2023 Jul 21]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526012/>

Shatterproof in collaboration with The Hartford (2021). Shatterproof Addiction Stigma Index. Boston, MA: Author. Accessed July 15, 2026, from: [Shatterproof-Addiction-Stigma-Index](#).

Sordo, L., Barrio, G., Bravo, M. J., Indave, I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. *BMJ*, 357, j1550. <http://dx.doi.org/10.1136/bmj.j1550>

South Central AETC/UT Health San Antonio. (2026). [Webpage]. *HIV Stigma-Free Health Care Series*. Accessed March 13, 2026, from: <https://aetc.uthscsa.edu/stigma-free-healthcare/>.

Substance Abuse and Mental Health Services Administration. (2021). *Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP)*. Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Author.

Substance Abuse and Mental Health Services Administration. (2025). [Webpage]. *Naltrexone*. Accessed March 13, 2026, from: <https://www.samhsa.gov/substance-use/treatment/options/naltrexone>.

Substance Abuse and Mental Health Services Administration. (2025). Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007, NSDUH Series H-60). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-surveydrug-use-and-health/national-releases>.

Sun, H.-M., Li, X.-Y., Chow, E., P., F., Li, T., Xian, Y., Lu, Y.-H., Tian, T., Zhuang, X., & Zhang, L. (2015). Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: A systematic review and meta-analysis. *BMJ Open*, 5(1), e005997. <https://doi.org/10.1136/bmjopen-2014-005997>

Tomiyama, A. J., Carr, D., Granbert, E. M., Major, B., Robinson, E., Sutin, A. R., & Brewis, A. (2018). How and why weight stigma drives the obesity ‘epidemic’ and harms health. *BMC Medicine*, 16(123).

Torruella, R. A. (2011). Xylazine (veterinary sedative) use in Puerto Rico. *Subst Abuse Treat Prev Policy*, 6, 7. <https://doi.org/10.1186/1747-597X-6-7>

Tosti, R., Hozack, B. A., Tulipan, J. E., Criner-Woozley, K. T., & Ilyas, A. M. (2024). Xylazine-associated wounds of the upper extremity: Evaluation and algorithmic surgical strategy.

Journal of Hand Surgery Global Online, 6(5), 605–609.

<https://doi.org/10.1016/j.jhsg.2024.05.003>

Trecki, J., Gerona, R. R., Ellison, R., Thomas, C., & Mileusnic-Polchan, D. (2022). *Notes from the Field: Increased Incidence of Fentanyl-Related Deaths Involving Para-fluorofentanyl or Metonitazene — Knox County, Tennessee, November 2020–August 2021*. *MMWR Morb Mortal Wkly Rep*, 71, 153–155. <http://doi.org/10.15585/mmwr.mm7104a3>

Trunfio, M., Chaillon, A., Beliakova-Bethell, N., Deiss, R., Letendre, S. L., Riggs, P. K., Higgins, N., & Gianella, S. (2023). Beyond the syndemic of opioid use disorders and HIV: The impact of opioids on viral reservoirs. *Viruses*, 15(8):1712. doi: 10.3390/v15081712. PMID: 37632053; PMCID: PMC10458944.

U.S. Food and Drug Administration. (2026). [Webpage]. *Information about Medications for Opioid Use Disorder*. Accessed March 13, 2026, from: <http://fda.gov/drugs/information-drug-class/information-about-medications-opioid-use-disorder-moud>.

Weiss, L., Egan J. E., Botsko, M., Netherland, J., Fiellin, D. A., & Finkelstein R. (2011). The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. *Journal of Acquired Immune Deficiency Syndromes*, 56(Suppl 1), S22–S32.

Wiley, R. (2017). [Video]. Rachel Wiley The Fat Joke. Accessed February 19, 2026, from: [Rachel-Wiley-The-Fat-Joke](#).

Woody, G. E., Bruce, D., Korthuis, P. T., Chhatre, S., Poole, S., Hillhouse, M., Jacobs, P., Sorensen, J., Saxon, A. J., Metzger, D., & Ling, W. (2014). HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. *Journal of Acquired Immune Deficiency Syndromes* 66(3), 288–293. <https://doi.org/10.1097/QAI.000000000000165>

Zoorob, R., Kowalchuk, A., & Mejia de Grubb, M. (2018). Buprenorphine therapy for opioid use disorder. *American Family Physician*, 97(5), 313–320.

Zwick, J., Appleseth, H. & Arndt, S. (2020). Stigma: How it affects the substance use disorder patient. *Subst Abuse Treat Prev Policy* 15, 50. <https://doi.org/10.1186/s13011-020-00288-0/>